Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, Crucell Sign Technology Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck, Crucell Sign Technology Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell has signed a cross-licensing agreement with Merck allowing Merck to use its technology on an exclusive basis in undisclosed vaccine fields. In turn, Crucell will receive access to Merck’s large scale manufacturing technology for its AdVac-based vaccines.

“This agreement will make it possible to speed up the delivery of our malaria and TB vaccines to the people in need, and makes it realistic to do so on the mass scale required,” said Jaap Goudsmit, chief scientific officer at Crucell. “It also opens the way for Crucell to speed up the Ebola program with the VRC, which has recently entered a Phase I trial. But most importantly, it brings the reality of vaccines such as these significantly closer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters